Clinical trials: Stem Cell Mobilization
Multiple Myeloma, Non-Hodgkin Lymphoma
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT01018979
- Testing
- TG-0054 (2.24 mg/kg), TG-0054 (3.14 mg/kg)
- Where
- 6 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- GPCR Therapeutics, Inc.
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Multiple Myeloma, Lymphoma, Non-Hodgkin's
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10^6…
- Trial name
- NCT00395967
- Testing
- G-CSF plus plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Myocardial Infarction
Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement
One emerging concept is that some form of injury or inflammation is a prerequisite for the success of circulating-cell participation in differentiated tissue structure and function.
- Trial name
- NCT00154466
- Testing
- cardiac rehabilitation
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Taiwan University Hospital
Beta Thalassemia Major, Congenital Anemias
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Betathalassemia major is a disease of the blood and bone marrow. You were born with it and it has made you unable to make normal hemoglobin and red cells. You have been receiving red blood cell transfusions all your life.
- Trial name
- NCT00658385
- Testing
- GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lysosomal Storage Diseases, Cystinosis
Stem Cell Gene Therapy for Cystinosis
This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis.
- Trial name
- NCT03897361
- Testing
- CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Multiple Myeloma, Non-Hodgkin Lymphoma
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT02104427
- Testing
- TG-0054 combined with G-CSF
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
Plasma Cell Myeloma, Multiple Myeloma
Collection of Transplant Stem Cells for Plasma Cell Myeloma
Background: One beneficial treatment for plasma cell myeloma is high-dose chemotherapy followed by stem cell transplant. Researchers want to collect stem cells from the blood for later transplant.
- Trial name
- NCT01547806
- Testing
- Filgrastim, Plerixafor, Apheresis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Lymphoma, Non-Hodgkin
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
This study will compare the results of stem cell mobilization using drugs called filgrastim (Neupogen) and plerixafor with the results of stem cell mobilization using drugs called XM02 filgrastim (Granix) and plerixafor.
- Trial name
- NCT02098109
- Testing
- XM02 Filgrastim, Filgrastim, Apheresis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine
Lymphoma, Non-Hodgkin
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal…
- Trial name
- NCT00103610
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 32 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Genzyme, a Sanofi Company
Sickle Cell Disease, Thalassemia
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Background: Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs.
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT02105766
- Testing
- Alemtuzumab, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Non-Hodgkin's Lymphoma, Plasma Cell Myeloma
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
This phase II trial studies how well stem cell transplant with or without tbo-filgrastim works in treating patients with multiple myeloma or non-Hodgkin lymphoma.
- Trial name
- NCT03317899
- Testing
- Hematopoietic Cell Transplantation, Tbo-filgrastim, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Multiple Myeloma
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies.
- Trial name
- NCT01146834
- Testing
- bortezomib (Velcade), cyclophosphamide, G-CSF
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Acute Myeloid Leukemia (AML)
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body…
- Trial name
- NCT00363467
- Testing
- G-CSF, Leukapheresis, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia (AML)
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors
The purpose of this study is to test a method of bone marrow transplantation that results in only temporary donor immune function.
- Trial name
- NCT02519712
- Testing
- Induction Chemotherapy, G-PBSC Infusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
The goal of this clinical research study is to learn if it is possible to collect stem cells after ofatumumab and chemotherapy treatment.
- Trial name
- NCT01329900
- Testing
- Ofatumumab, Ifosfamide, Etoposide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Blood And Marrow Transplantation
Plerixafor for Stem Cell Mobilization in Normal Donors
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself.
- Trial name
- NCT01818284
- Testing
- Filgrastim, Plerixafor, Apheresis Procedure
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Neoplasms
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.
- Trial name
- NCT00914849
- Testing
- AMD3100, Leukopheresis, Stem cell transplant
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine